ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Rating of "Moderate Buy" from AnalystsMarket Beat·1 day ago, 01:14 AMANIP-1.12%
Two Years to Build or Pay 200% — Which US Pharma Stocks Win?benzinga_article·2 days ago, 05:25 AMAMPH-0.79%ANIP-1.12%
Sanctuary Advisors LLC Takes Position in ANI Pharmaceuticals, Inc. $ANIPMarket Beat·2 days ago, 03:52 AMANIP-1.12%STT+0.65%
ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET | ANIP Stock NewsStockTitan·2 days ago, 09:50 PMANIP-1.12%
ANI Pharmaceuticals SVP, General Counsel Meredith Cook disposes of 500 common shares for $40,920PUBT·Jul 14 at 03:02 PMANIP-1.12%
ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious UveitisGlobeNewswire·Jul 13 at 05:50 AMANIP-1.12%
ANI Pharmaceuticals (ANIP) Recalls HydrOXYzine Solution, Is The Pullback A Valuation Opportunity?Simplywall·Jul 10 at 12:02 PMANIP-1.12%
ANI Pharma SVP, CFO Stephen P. Carey disposes of 3,313 common shares worth $284,918PUBT·Jul 6 at 08:41 PMANIP-1.12%
